BOOT posts strong Q3 results with 16% sales growth, fueled by omnichannel gains and rising exclusive brand sales.

Apple and Alphabet have reached a deal to allow Google Gemini to power Siri's AI. The companies said the deal would power features coming this year.

Tree.com (TREE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Alphabet has entered into a multi-year deal with Apple where the next generation of the iPhone maker's AI models will be based on Google's Gemini models, Alphabet said on Monday.

The story is about whether Firefly Aerospace Inc. can build a stable operating model not about near-term profits. FLY stock value depends on improving execution and achieving a stable and repeatable operating pace. Management has shifted toward execution, quality control and process discipline after early delays, which is critical for credibility and revenue stability.

AUSTIN, Texas--(BUSINESS WIRE)--Navan, Inc. is under investigation for potential false or misleading statements in its IPO registration statement by Highful Law PLLC.

The main metal commodity story dominating 2025 is unquestionably the huge price escalation of gold (~+70%) and silver (~+169%).

Today, it will be about the US Dollar and the headlines coming out of the Department of Justice in America.

Walmart (NASDAQ:WMT) shares are up 2.6% to trade at $117.50, at last check, powered by two recent developments shedding light on its tech-driven transformation.

Floor & Dcor (FND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Wedbush has reiterated its 'outperform' rating on Apple Inc (NASDAQ:AAPL, XETRA:APC), arguing that the tech giant is on the brink of a major growth cycle driven by artificial intelligence and underpinned by the strength of its services business. In a detailed note to clients, analysts at the US broker said Apple is entering what they call an “AI-driven renaissance”, with a raft of new AI-powered features expected to be introduced across iPhone and Mac devices in 2026.

Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using Biohaven's proprietary MoDE™ and next-generation, highly selective TRAP™ degraders exclusively licensed from Yale University. Early clinical experience in patients demonstrates rapid removal of circulating disease-causing proteins, resulting in robust clinical improvement with a well-tolerated profile to date: IgA Nephropathy (IgAN) Program: First dosing of BHV-1400 TRAP degrader in IgAN patients achieved early observations of both biomarker and clinical responses including: selective lowering of only the disease-causing galactose-deficient IgA1 (Gd-IgA1) while sparing off-target effects on healthy antibodies (IgA, IgM, IgE, IgG), resolution of blood in the …

Optimism about its growing AI business gave the Google parent entry to a rarefied club.

The active ETF market split along strategy lines in 2025, with discretionary equity funds gaining 3.3% market share while systematic equity funds lost 1.1%, according to Morningstar data shared by Ben Johnson, head of client solutions and asset management at the firm. The divergence shows not all active strategies performed equally, with the T.

RADNOR, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V. (NASDAQ: QURE) (“uniQure”).

Teva strikes a $500M funding deal with Royalty Pharma for the speedy development of its vitiligo candidate, TEV-'408, while keeping global commercial control.

Meta on Monday appointed banker Dina Powell McCormick as president and vice chairman, tapping a former member of the Trump administration to help steer the technology giant's massive AI infrastructure expansion.

Quince Therapeutics is rated Buy ahead of its pivotal Phase 3 NEAT trial readout in Ataxia-Telangiectasia (A-T) expected mid-Q1 2026. eDSP, QNCX's lead asset, offers chronic corticosteroid delivery with reduced toxicity, targeting a $1B+ orphan market with no approved therapies. The NEAT trial addresses prior design flaws, is 90% powered for statistical significance in 6-9 year-olds, and enjoys strong regulatory alignment.

It's a bird. It's a plane.

Franklin Covey Co. remains a Buy despite recent underperformance, with the market overlooking deferred revenue growth and sales strategy improvements. FC's transition to a split sales team and focus on new logos is driving a 25% increase in new client invoicing and higher service attach rates. Deferred revenue and multiyear contract metrics signal increasing customer stickiness, even as short-term margins and cash flow remain pressured.